Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.42 |
| ▸ | FAP | Q12884 | 3/20 | 0.42 |
| ▸ | PREP | P48147 | 2/20 | 0.42 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14655949 | 0.86 | DPP4 (0.53) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL14655953 | 0.84 | DPP4 (0.61) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL14656008 | 0.84 | DPP4 (0.61) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL9901341 | 0.83 | DPP4 (0.50) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL19652203 | 0.82 | MEN1 (0.43) | DPP4 | |
| SCHEMBL2456457 | 0.82 | DPP4 (0.56) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL2456462 | 0.82 | DPP4 (0.56) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL15203513 | 0.80 | DPP4 (0.55) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL22630456 | 0.79 | ALDH1A1 (0.61) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL17787623 | 0.79 | ALDH1A1 (0.61) | DPP4DPP7DPP8DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11292783-B2 | Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists | RESEARCH TRIANGLE INSTITUTE (NC) | 2022-04-05 | — | — | US | disclosed |
| EP-3512832-B1 | TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS | RES TRIANGLE INST (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20190263781-A1 | Tetrahydroisoquinoline Kappa Opioid Antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2019-08-29 | — | — | US | disclosed |
| WO-2018053222-A1 | TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS | RESEARCH TRAINGLE INSTITUTE (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11292783-B2 | Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists | OPRK1, OPRD1, OPRM1 | DPP4 3504/4885DPP7 4157/4885DPP8 4369/4885 |
| US-20190263781-A1 | Tetrahydroisoquinoline Kappa Opioid Antagonists | OPRK1, OPRD1, OPRM1 | DPP4 3757/4885DPP7 4144/4885DPP8 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.